The eighth edition of the American Joint Committee on Cancer (AJCC) distant metastases (M) stage classification for metastatic pancreatic neuroendocrine tumors might be feasible for metastatic pancreatic ductal adenocarcinomas.
Significant modifications have been made in the eighth edition of the American Joint Committee on Cancer (AJCC) distant metastases (M) stage classification for metastatic pancreatic neuroendocrine tumors (Pan-NET). We aimed to validate this revised classification among metastatic Pan-NET patients using the Surveillance, Epidemiology, and End Results (SEER) database. We further sought to evaluate the feasibility of applying this classification to metastatic pancreatic neuroendocrine carcinoma (Pan-NEC) and pancreatic ductal adenocarcinoma (PDAC) patients. Stage IV pancreatic neuroendocrine neoplasm (Pan-NEN, including G1/G2 Pan-NET, G3 Pan-NEC classified according to the WHO 2010 grading scheme) and PDAC patients with metastatic disease diagnosed between 2010 and 2015 were identified and restaged according to the revised M stage classification for Pan-NET. Overall survival (OS) was compared using the Kaplan-Meier analysis and log-rank test. Univariate and multivariate Cox regression models were utilized to identify prognostic factors. A total of 1371 stage IV Pan-NEN and 634 PDAC patients were included. Among Pan-NEN patients, liver (75.0%) was the most common metastatic site, followed by distant lymph node (8.5%), lung (8.4%), bone (7.3%) and brain (1.0%). The 5-year OS for Pan-NET patients with M1a, M1b and M1c stage were 44.15%, 53.32% and 19.70%, respectively. However, a survival comparison showed no significant difference between M1a and M1b stages among Pan-NET patients. Similar findings were noted after applying this classification to Pan-NEC patients. Multivariate analysis showed that the age at diagnosis and the number of distant metastatic sites were independent prognostic factors for metastatic Pan-NEN patients. Interestingly, excellent survival discrimination by M stage among stage IV PDAC patients was noted (M1a vs. M1b vs. M1c, 5-year OS: 5.42%, 2.46% and 0, respectively). Our study is the first large-sample size based validation of the AJCC 8th M stage classification for Pan-NET. The revised classification did not effectively stratify metastatic Pan-NEN patients. However, further study is warranted to validate this classification for Pan-NET patients according to the WHO 2017 classification. Interestingly, the revised M stage classification might be feasible for PDAC patients with metastatic disease.